On July 9, 2002, the front pages of nearly every newspaper in America carried the same frightening message: Hormone replacement therapy causes breast cancer.
The federal government had stopped a major study early, announcing that women taking hormone replacement therapy (HRT) faced a 26% increased risk of breast cancer. Overnight, millions of women threw away their prescriptions.
There was just one problem.
That interpretation wasn’t accurate. Over the next two decades, the original findings of the $725-million Women’s Health Initiative (WHI) began to fall apart.
But the damage was done. Two generations of women suffered needlessly through hot flashes, bone loss, and cardiac decline.
Key Takeaways
- The 2002 WHI study focused on one specific drug, older women far past menopause, and a fixed dose.
- The corrected science shows hormones are safe when prescribed correctly.
- At Castle Rock Hormone Health, we use personalized testing and hormone optimization plans to ensure HRT is safe.
What Was the Women’s Health Initiative HRT Study?
In 1993, the National Institutes of Health launched the Women’s Health Initiative hormone replacement therapy research project. They recruited more than 27,000 women across the United States. The goal was to figure out once and for all whether hormone therapy helped prevent chronic disease in older women.
At the time, doctors had good reason to think it might. Earlier research, including the long-running Nurses’ Health Study, suggested that women taking estrogen had nearly 50% lower rates of heart disease.
Hormones were already FDA-approved for treating hot flashes and night sweats, and millions of women were using them. The WHI was designed to test whether those benefits held up in an experiment.
Here is what most people don’t know: The WHI actually contained two separate hormone experiments:
- Experiment 1: Estrogen + Progestin (EPT). This was for women with a uterus, included 16,608 women, and tested a synthetic drug called Prempro.
- Experiment 2: Estrogen Alone (ET). This was for women who had their uterus removed. It included 10,739 women and tested another synthetic drug called Premarin.
The estrogen-only trial continued until 2004. The estrogen-plus-progestin trial was stopped in 2002, three years early. The results were announced at a press conference before most scientists had even seen the full data.
That press conference changed everything. Here is what the WHI actually found in 2002, in the estrogen-plus-progestin experiment:
| Outcome | Relative Risk | Absolute Risk (per 10,000 women/year) |
|---|---|---|
| Breast cancer | 26% | +8 cases |
| Heart attack | 29% | +7 events |
| Stroke | 41% | +8 events |
| Blood clots | 111% | +18 events |
| Colorectal cancer | 37% | -6 cases |
| Hip fractures | 34% | -5 fractures |
This meant that for every 10,000 women taking Prempro for one year, eight more would get breast cancer, seven more would have heart attacks, and eight more would have strokes. But six fewer would get colon cancer, and five fewer would break a hip.
That’s not nothing. But it’s also not “hormones cause cancer.” Yet these findings were applied to every woman, of every age, taking any form of hormones, for any reason.
What the Women’s Health Initiative Got Wrong About HRT
The Women’s Health Initiative was a study of one specific drug, in one specific age group, using one specific route of administration, for one specific purpose (disease prevention in asymptomatic women).
It wasn’t a study that should’ve been applied to every woman, but that’s how the results were presented. Here is what the WHI study actually studied and what it missed.
1. It Tested One Drug, One Dose, One Route, Then Generalized the Results
You might assume that a $725 million government study testing something as widely used as hormone therapy would have tested, well, hormone therapy. It didn’t. The WHI tested one drug: Prempro.
Prempro is a specific formulation made by Wyeth-Ayerst. It combines two things:
- Conjugated equine estrogen (estrogen extracted from pregnant horse urine)
- Medroxyprogesterone acetate, or MPA (a synthetic progestin)
This medication was provided as an oral, fixed dose, with 0.625 milligrams of estrogen and 2.5 milligrams of MPA, every single day for every woman in the study. That is not “HRT.” It’s one version of HRT.
The WHI did not study the effects of transdermal estrogen, micronized progesterone, bioidentical progesterone, lower doses, cyclic dosing, estradiol, or testosterone, all of which HRT uses.
The study looked at the effects of one drug on older women, yet blanket applied the findings (which were flawed) to every woman.
What Your Doctor Won’t Tell You About Testosterone Levels in Women
2. The Women Were Already Past Menopause
The average age of women in the WHI estrogen-plus-progestin trial was 63. In fact, two-thirds of them were over 60. Most were 12 to 15 years past menopause. These were not women looking for relief from hot flashes.
These were women whose hot flashes had come and gone years earlier. They did not join the study because they were suffering. Instead, they were volunteers, willing to be randomized to hormones or a placebo for the sake of science.
And here is what the study found: When you give hormones to a 65-year-old woman who is 15 years past menopause and has no symptoms, you do not see benefits. You see risks. This is what researchers now call the “timing hypothesis.” Here is what it means:
- If you start hormones close to menopause, your body recognizes them. Your blood vessels are still healthy, and estrogen is protective.
- If you start hormones a decade or more after menopause, your blood vessels have aged, plaque may have developed, and estrogen can destabilize that plaque.
The WHI did not test the first scenario. It tested the second, then it applied findings from that group to women in their 40s and 50s who were actively suffering.
3. The Participants Were Overweight
The average BMI of women in the WHI estrogen-plus-progestin trial was 28.5. They were representative of average American women in their 60s and 70s.
Their weight wasn’t the problem. The problem was that weight itself is a risk factor for breast cancer.
In fact, in postmenopausal women, obesity is associated with a 20% to 40% increase in estrogen receptor-positive breast cancer. This happens because fat tissue produces estrogen. So more fat tissue means more circulating estrogen, and more estrogen means more fuel for hormone-sensitive breast cancers.
Weight is also a risk factor for heart disease. Obesity doubles to triple the risk of heart attack and stroke.
But the WHI study design failed to account for all of this. A fair study would have acknowledged that age, weight, and prior hormone use all influence outcomes.
4. The Absolute Risk Was Tiny
In May 2002, an independent committee monitoring the WHI study noticed something. Women taking Prempro were being diagnosed with breast cancer at a slightly higher rate than women taking the placebo.
The difference was eight additional cases per 10,000 women per year. On July 9, 2002, the study was stopped early. Three days later, the findings were published in the Journal of the American Medical Association.
But the number they put in the headline was not eight per 10,000. It was 26%. Here is what those two numbers actually mean:
- If you gathered 10,000 women who were not taking hormones, 30 of them would be diagnosed with breast cancer that year.
- If you gathered 10,000 women who were taking Prempro, 38 would be diagnosed with breast cancer.
That eight-woman difference is the “26% increase” you heard about. Over five years, that’s about four extra diagnoses per 1,000 women. That’s not zero risk, but it’s also a long way from “hormones cause cancer.”
Plus, when researchers took a closer look in 2006, they found that the increased risk was not spread evenly. It was almost entirely concentrated in one group: women who had taken hormones years before, then stopped, then joined the study and were put back on Prempro.
Among women who had never taken hormones before, there was no statistically significant increase in breast cancer risk at all.
5. The Estrogen-Only Arm Told a Completely Different Story but Got Buried
When the WHI halted part of its hormone trial in July 2002, what received far less attention was that the WHI was not a single study. It was two parallel trials. One tested estrogen plus a synthetic progestin in women with a uterus. That was the arm that stopped early.
When the estrogen-only results were published, they found no increase in breast cancer. In fact, women assigned to estrogen alone had 23% fewer breast cancer diagnoses than those on placebo.
Long-term follow-up told a similar story. Over nearly 20 years, women in the estrogen-only group had approximately a 40% lower risk of dying from breast cancer compared with women who did not take hormones.
What Later Research Revealed About HRT and Breast Cancer
Five years after the 2002 press conference, WHI investigators went back to the data and asked a different question: What happens when you look at women by age?
They found that women in their 50s who took hormones did not have a higher risk of heart attack. In fact, they had a lower heart attack risk and a 30% lower risk of dying from any cause than women who didn’t take hormones.
The problem was never hormones. The problem was giving them to women decades past menopause and pretending that told us something about women during menopause. Once researchers started studying the right population, the risk profile looked very different.
Other studies began to test that timing more directly.
A Danish randomized trial followed 1,006 recently menopausal women who started estradiol therapy soon after menopause. Over time, researchers observed:
- Reduced risk of heart failure
- Reduced risk of heart attack
- Reduced overall mortality
- No increase in breast cancer, with a trend toward fewer cases
The Kronos Early Estrogen Prevention Study took a similar approach. It enrolled women aged 42 to 58, all within three years of menopause, and tested different forms of estrogen. Researchers found improved cholesterol profiles and no increased risk of breast cancer or heart disease.
These findings showed that hormone therapy appeared to carry different risks and benefits depending on when it is started.
The 2020 WHI long-term follow-up put the issue of HRT to rest. It concluded that estrogen alone reduced breast cancer risk by 23%, breast cancer death by 40%, and all-cause mortality for women.
It also found that while estrogen plus progestin therapy could lead to a small increase in breast cancer diagnoses, it didn’t increase breast cancer death risk. It was also actually cardio-protective when started under 60, and reduced fractures.
“Hormones play a big role in bone health, cardiovascular health,” Dr. Kelli agrees. “They prevent fractures in our elderly women and improve cardiac health, which has been worsening for women over the last several years.”
Let Castle Rock Help You Understand What the Corrected WHI Means for You
The WHI study does not tell you what will happen to you. It tells you what happened, on average, to women who were further past menopause than you probably are.
Your body is not their body. Your risk profile is not their average. And the hormones available today are not the single pill they tested in 2002.
What Should You Do Next?
If you have been suffering in silence because you were told hormones are dangerous, here are three things you can do right now:
- Stop carrying the 2002 headlines as if they were your medical history. Science has moved on. You have permission to move on with it.
- Write down what you’re feeling. The hot flashes that wake you at 3 AM and the brain fog that makes you feel like you’re losing a step aren’t just signs you’re “getting older.”
- Talk to our experts at Castle Rock Hormone Health. We’ve lived through the 2002 panic, watched the science correct itself, and can help you understand what will work for your body.
At Castle Rock Hormone Health, we believe in giving your body what it needs to function the way it was designed to. This is why we start with your symptoms and use the right testing to see what your hormones are actually doing.
Once we understand what optimal looks like for your body, we build a personalized plan using modern hormone formulations.
Lab testing is included in your membership, so we can monitor your progress and adjust as needed without surprise bills or unnecessary visits. You don’t need to push harder or accept low energy as your new normal.
Book your free evaluation to understand what the corrected science means for your body, health, and life.
“This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider, such as Dr. Lee Moorer, regarding any medical concerns.”
